PhaseV to Present AI Advances in Clinical Development Optimization at Upcoming Biotech and Data Science Events

Presentations Will Demonstrate Effective Use of Machine Learning and Adaptive Clinical Trial Design to Enhance Precision and Efficiency in Drug Development 

BOSTON, Feb. 6, 2025 /PRNewswire/ -- PhaseV, a pioneer in software and machine learning (ML) for advanced clinical development optimization, announced today that senior company executives will present at five key industry conferences in the first half of 2025, demonstrating expertise in causal inference and adaptive machine learning tools to enhance the efficiency and success of clinical trials.

"Applying machine learning to improve clinical development is no longer just a vision. It's here and its success depends on proper development of tools that meet the sector's unique needs," said Raviv Pryluk, PhD, CEO and Co-founder of PhaseV. "We're excited to share our proprietary data-driven approach and results at these leading conferences as we continue expanding our global collaborations with leading biotech and pharma companies, as well as CROs, while presenting the value we bring to clinical development."

Details of the presentations are as follows:

• Drug R&D 2025
  February 10–12, Boston, MA
  Presentation: AI in Clinical Trial Design
  Speaker: Raviv Pryluk, PhD, CEO and Co-founder of PhaseV

• Adaptive Designs and Multiple Testing Procedures Workshop (ADMTP)
  February 26-27, Regensburg, Germany
  Presentations:
  - Exploratory Adaptive Enrichment Design with Sample Size Re-estimation: A Novel Approach for Clinical Trial Optimization
  Speaker: Elad Berkman, PhD, CTO and Co-founder of PhaseV
  -   Model-Guided Parameter Optimization for Complex Innovative Trial Designs
  Speaker: Raviv Pryluk, PhD, CEO and Co-founder of PhaseV

• Eastern North American Region (ENAR) 2025 Spring Meeting
  March 23-26, New Orleans, LA
  Topic: Adaptive Clinical Trial Designs Using Stepwise Monte Carlo for Increased Flexibility and Robustness
  Speaker: Brad Carlin, PhD, Senior Director

• Chief Medical Officer (CMO) Summit 360⁰
  April 7-8, Boston, MA
  Topic: Reimagining Clinical Trials: How AI and ML Drive Precision, Efficiency, and Success
  Speaker: Raviv Pryluk, PhD, CEO and Co-founder of PhaseV
  PhaseV will also exhibit at booth 11

• Duke Industry Statistics Symposium (DISS2025)
  April 9-11, Durham, NC
  Topic: Recent Advances in Computing, Optimization, and Causal Inference for Adaptive Clinical Trials
  Speakers: Raviv Pryluk, PhD, CEO and Co-founder of PhaseV; Brad Carlin, PhD, Senior Director, Data Science and Statistics at PhaseV; Yaniv Fogel, Algo Team Lead at PhaseV

Since its founding, PhaseV has become a trusted partner for over 30 global pharma and biotech companies, including 7 industry leaders that are using the company's ML-powered platform to optimize clinical trials.

About PhaseV
Leveraging the power of advanced causal inference and pushing the boundaries of ML, PhaseV detects hidden signals in clinical data and extracts actionable insights for planning the optimal next steps. The company's technology enables optimal design and closed-loop execution of adaptive clinical trials, increasing efficiency and success rates. PhaseV is advancing paradigm shifts in the clinical trial world to bring new treatments to more patients in a more precise and efficient way.

Learn more at www.phaseVtrials.com and follow us on LinkedIn.

Media Contact: 
Ellie Hanson
FINN Partners for PhaseV
[email protected]
929-588-2008

Logo - https://mma.prnewswire.com/media/2267452/5074889/PhaseV_logo.jpg

SOURCE PhaseV